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(propensity scoring, standard and conditional logistic regression,
and Cox proportional hazards function). Control variables
included: demographics (age, gender, race, and region), general
health comorbidities (hypertension and dyslipidemia), mental
health comorbidities (bipolar disorder, depression, post-
traumatic stress disorder, schizophrenia, and substance abuse),
antipsychotic drug utilization patterns (monotherapy, switching,
and combination therapy), treatment duration, medication re-
exposure, and treatment initiation year. Claims databases from
the Veterans Administration North Texas Health Care System
and the South Texas Veterans Health Care System (1995–2004)
were used. RESULTS: Of the eligible patients (N = 8949), regard-
less of variations in methodologies of the seven models, there
were no signiﬁcant differences in diabetes risk among patients
who were: 1) initiated on the second generation antipsychotics
(SGAs) compared to those on the ﬁrst generation antipsychotics
(FGAs); 2) initiated on olanzapine compared to those on risperi-
done; and 3) exposed to olanzapine or quetiapine compared to
those exposed to FGAs. Inconsistent results among the models
were observed when comparisons were made between: 1)
patients initiated on quetiapine (increased risk vs. no difference)
compared to those on risperidone, and 2) patients exposed to
risperidone (decreased risk vs. no difference) compared to those
exposed to FGAs. Differences occurred among the following.
METHODS: ITT retrospective cohort and ITT case-control; and
AT retrospective cohort and AT case-control. CONCLUSIONS:
With respect to antipsychotic utilization, results of the various
models using different methodologies were largely consistent.
Advantages and disadvantages of the seven models will be 
presented.
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OBJECTIVE: To examine whether the relationship between
antipsychotic utilization and treatment-emergent diabetes among
patients newly initiated on therapy varied, when propensity
scoring was (Model I) and was not (Model II) used. METHODS:
Claims databases from the Veterans Administration North Texas
Health Care System and the South Texas Veterans Health Care
System (1995–2004) were used. Both Models I and II utilized a
retrospective cohort design and an intent-to-treat method to
assign treatment exposure. Covariates included demographics
(age, gender, race, and region), general health comorbidities
(hypertension and dyslipidemia), mental health comorbidities
(bipolar disorder, depression, post-traumatic stress disorder,
schizophrenia, and substance abuse), antipsychotic drug utiliza-
tion patterns (monotherapy, switching and combination
therapy), treatment duration, medication re-exposure, and treat-
ment initiation year. Logistic regression was used to analyze data.
RESULTS: Eligible patients (N = 8949) had a 6.0% annual dia-
betes incidence rate. No signiﬁcant difference was found in dia-
betes risk between patients treated with the ﬁrst generation
antipsychotics (FGAs) and the generation antipsychotics (SGAs).
Findings were consistent among most covariates. In both models,
when compared to monotherapy, antipsychotic combination
therapy increased diabetes risk, while switching did not. Antipsy-
chotic re-exposure, early treatment initiation years, and a shorter
treatment duration were associated with an increased diabetes
risk. Results varied with the following two variables: nonwhites
were associated with an increased risk in Model I, while there
was no association in Model II; depression was associated with
an increased risk in Model II, while there was no association in
Model I. All other variables were not signiﬁcant and were con-
sistent between the two models. CONCLUSIONS: SGAs were
not associated with an increased diabetes risk when compared
to FGAs. Including propensity scoring in a retrospective cohort
design may alter the results of some covariates; however, it did
not change the results regarding the class of antipsychotics uti-
lized and risk of diabetes mellitus.
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OBJECTIVES: The objective is to examine the performance of
a variety of ﬁlters used in digital signal processing and evaluate
the ﬁlter coefﬁcients as potential indices of glycemic control.
Digital signal processing has played an extensive role in sepa-
rating signal from noise in biological signals for decades. Cas-
caded adaptive ﬁlters, high pass ﬁlters, Kalman ﬁlters as well as
discrete Fourier transforms have been used to produce clean
signals and obtain the frequency spectrum for ECG signals. With
the rapid advances in Continuous Glucose Monitoring (CGM)
sensors, a nearly continuous stream of glucose levels is made
available with wavelike postprandial excursions. Extraction of
key information beyond descriptive statistics from the mass of
glucose data has been illusive. This is no clean classiﬁcation as
in the case of cardiac arrhythmias. Little prior work in the
medical literature exists except a Kalman ﬁlter simulation using
a sinusoidal function to represent a postprandial excursion
(Palerm, 2005), and a brief note by Knobbe (2005) discussing
Kalman ﬁlters in CGM. METHODS: The mathematical form of
each ﬁlter is presented along with identiﬁcation of associated for-
mulas for each of their ﬁlter coefﬁcients, a table of characteris-
tic ﬁlter coefﬁcients, coefﬁcient ranges, stability and evidence of
substantive interpretability. Archetype postprandial excursions
are represented by truncated Taylor series. RESULTS: Charac-
teristics compared include: stability of ﬁlter coefﬁcient under
trivial curve variation representing the post-prandial excursion
waveform, range of values, sensitivity to substantial variation in
the waveform, usefulness in combination with other statistics
and sensitivity and speciﬁcity in predicting hypoglycemic events.
CONCLUSIONS: Several signal processing ﬁlters appear to be
effective for extraction of information from CGM series, and
some of these appear promising as a basis for new indices of
glycemic control and for classiﬁcation of patients and effects of
medications such as rapidly acting insulin analogs that blunt the
post-prandial excursions.
DIABETES—Patient Reported Outcomes
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OBJECTIVE: Studies have indicated that independent pharma-
cies outperform chain pharmacies in one-on-one personal atten-
tion and quality of patient counseling. However, there are no
studies examining whether these beneﬁts translate into outcomes
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such as improved medication adherence. The objective of this
study was to estimate the impact of type of pharmacy
(chain/independent) on adherence to Oral Hypoglycemic Agents
(OHAs) in patients newly diagnosed with type 2 diabetes.
METHODS: Newly diagnosed type 2 diabetes patients during a
four-year period were identiﬁed from a Medicaid claims data-
base. The provider of the index prescription was classiﬁed as a
chain or independent pharmacy. Utilization patterns (switching,
augmentation, discontinuation, non-modiﬁcation) and adher-
ence to OHAs (Medication Possession Ratios) were computed
for a 12-month follow-up period from the date of the index
OHA prescription. A multivariate framework was used to esti-
mate the impact of type of pharmacy on utilization patterns and
adherence, controlling for demographics, co-morbidity, diabetes
severity, and regimen complexity. RESULTS: A total of 1214
newly diagnosed type-2 diabetes patients were identiﬁed (inde-
pendent pharmacy = 430; chain pharmacy = 784). Utilization
patterns were not signiﬁcantly different between patients ﬁlling
their prescriptions at an independent pharmacy versus those
ﬁlling prescriptions at a chain pharmacy. Independent-sample t-
tests indicated that adherence to OHAs (Mean ± S.D) was sig-
niﬁcantly higher for patients ﬁlling their prescriptions at a
independent pharmacy (0.90 ± 0.11) as compared to those ﬁlling
prescriptions at a chain pharmacy (0.87 ± 0.13) [p = 0.02].
Results of a semi-log OLS model indicated that controlling for
covariates, patients ﬁlling prescriptions at an independent phar-
macy had 2.30% higher adherence to OHAs as compared to
those ﬁlling prescriptions at a chain pharmacy [p = 0.04]. CON-
CLUSION: Patients ﬁlling prescriptions at independent pharma-
cies have signiﬁcantly higher adherence to OHAs as compared
to those ﬁlling prescriptions at chain pharmacies. This improved
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications.
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OBJECTIVES: Long-term adherence to medications among type
2 diabetes patients may have an impact on health care costs and
hospitalizations. This study examined differences in medication
adherence, and persistence, hospitalization and health care costs
between patients with type 2 diabetes enrolled in the North Car-
olina Medicaid newly starting thiazolidinedione (TZD) therapy
and those starting other oral antidiabetic agents. METHODS: A
total of 1774 patients newly starting TZD therapy between July
2001 and June 2002 were compared to 218 patients starting met-
formin and 1199 patients starting sulfonylureas for health care
costs and outcomes in the post-medication start year. The
cohorts were followed for 30 months (July 2002 to December
2004) to examine if there were any differences in outcomes such
as adherence, persistence, hospitalization and total health care
costs that could be associated with type of therapy. Multivariate
regression techniques incorporating health care utilization in the
year prior to start of new therapy were utilized to determine 
the net cost impact of one therapy versus the other. RESULTS:
The average health care costs were less for patients on TZD
[836.34 (1176.30)] as compared to other two groups. Persistence
and adherence rate to TZDs was similar to other Sulfonylureas,
and higher than Metformin. Multivariate analysis showed that
patients on TZD therapy had signiﬁcantly higher medication
adherence while metformin users had signiﬁcantly lower med-
ication adherence as compared to sulfonylureas. Patients on
TZD therapy were associated with decreased likelihood of hos-
pitalization and decreased number of hospitalizations as com-
pared to sulfonylureas users. Adherence to new therapy was
signiﬁcantly associated with decreased number of hospitaliza-
tions. CONCLUSIONS: Long-term use of thiazolidinedione
therapy in a Medicaid-enrolled type 2 diabetic population was
associated with signiﬁcantly greater treatment adherence, and
reduced hospitalization in the post-start year compared to
patients starting other oral antidiabetic agents.
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OBJECTIVE: Medication adherence is an important factor in
improving outcomes among type 2 diabetes patients. The
primary objective of this study was to determine the association
between race and medication adherence among type 2 diabetes
patients. The secondary objectives were to determine the associ-
ation between type of therapy and medication adherence and to
determine if race has an inﬂuence in determining the medication
adherence to speciﬁc antidiabetic therapy. METHODS: This ret-
rospective cohort study was conducted using North Carolina
Medicaid prescription claims. A total of 1774 patients newly
starting Thiazolidinediones were compared to 216 patients start-
ing metformin and 1179 patients starting Sulfonylureas. Med-
ication adherence was measured as Medication Possession Ratio
using prescription reﬁll patterns. Multivariate regression analy-
ses were used to determine the difference in adherence rates
adjusting for other covariates. RESULTS: Whites’ had highest
mean medication adherence rate of 59% which was signiﬁcantly
different from Blacks (54%) (p < 0.05). Thiazolidinediones’
adherence rate of 60% was signiﬁcantly higher than metformin
(22%) and sulfonylurea group (57%) (both p < 0.05). Whites
had higher adherence to all the therapies as compared to other
two races. In multivariate analyses, the adherence rate of black
patients was found to be signiﬁcantly lower by 12% as compared
to whites after adjusting for other variables (p < 0.05). Met-
formin users were associated with 62% decrease in adherence
rate as compared with the sulfonylurea group and 63% decrease
in adherence rate as compared with thiazolidinediones (both p <
0.05). CONCLUSION: Antidiabetic medication adherence was
associated with race as well as type of therapy. Future research
should focus on investigating patient-related and therapy-related
factors affecting medication adherence in type 2 diabetes
patients.
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OBJECTIVE: The purpose of this study was to determine the
extent of adherence among diabetic patients to treatments and
